CMTX1 patients’ cells present genomic instability corrected by CamKII inhibitors
- Mones Saleh†1,
- Gess Burkhardt†2, 3,
- Bordignon Benoit1,
- Altié Alexandre4,
- Young Peter2,
- Bihel Frederic5,
- Fraterno Marc2,
- Peiretti Franck1 and
- Fontes Michel1Email author
© Saleh et al. 2015
Received: 25 February 2015
Accepted: 16 April 2015
Published: 7 May 2015
We previously described that fibroblasts from animal models of CMTX1 present genomic instability and poor connexon activity. In vivo, these transgenic mice present motor deficits. This phenotype could be significantly reverted by treatment with (CamKII) inhibitors. The objective of this study is to translate our findings to patients.
We cultured fibroblasts from skin biopsies of CMTX1 patients and analyzed cells for genomic instabilty, connexon activity, and potential correction by CamKII inhibitors.
The phenotypic analysis of these cells confirmed strong similarities between the GJB1 transgenic mouse cell lines and CMTX1 patient fibroblast cell lines. Both present mitotic anomalies, centrosome overduplication, and connexon activity deficit. This phenotype is corrected by CamKII inhibitors.
Our data demonstrate that fibroblasts from CMTX1 patients present a phenotype similar to transgenic lines that can be corrected by CamKII inhibitors. This presents a track to develop therapeutic strategies for CMTX1 treatment.
KeywordsCMT disorder Peripheral neuropathies Drug development
We recently created and analyzed transgenic mouse lines that expressed a human mutated GJB1  (i.e., the gene involved in the X-linked form of Charcot-Marie-Tooth disease ), coding for connexin 32 (Cx32), a component of gap junctions [3,4]. We demonstrated that Cx32 is involved in mitotic stability, as transgenic cells present mitotic instability (i.e., aneuploidy, or centrosome overduplication). Both our study and the European Mitocheck project (www.mitocheck.org) observed that a lower Cx32 expression or expression of a mutated isoform resulted in perturbation of cell division [1,5].
Moreover, in a recent article , we suggested that this instability is due to CamKII overexpression, thereby leading to centrosome overduplication. In 1997, Torok et al.  identified two calmodulin-binding domains in Cx32 and provided evidence that calmodulin may function as an intracellular ligand, regulating Ca2+-dependent intercellular communication across gap junctions. Finally Dodd et al.  demonstrated that the physical proximity between Cx32 and Calmodulin Kinase II (CamKII) had a physiological role. It was thus likely that pathological mutations in Cx32, associated to CMTX1, resulted in mitotic instability through CamKII overexpression that led to centrosome overduplication. Furthermore, we demonstrated that treatment with CamKII inhibitors  (KN62 or KN93 ) resulted in a partial but significant rescue of abnormal centrosome overduplication, mitotic instability, and connexon activity. In addition, in vivo treatment of CMTX1-related transgenic mice with KN93 improved their locomotor performance on the rotarod.
However, these data were either obtained from transgenic mouse lines (i.e., our findings) or human transfected cells (i.e., the Mitocheck project). We could thus not presume that these findings could be translated to CMTX1 patients. We thus collected and analyzed fibroblasts from the skin biopsies of five CMTX1 patients that presented three different mutations. Phenotypic analysis of the patient’s cells were compared to phenotypic presentation of the cells from CMTX animal models. Phenotypic correction using CamKII inhibitors was also tested.
Patients were evaluated at the University Hospital of Muenster. The inclusion criteria for this study required a clinical phenotype consistent with CMT and a genetic diagnosis of CMTX1. Nerve conduction studies (NCS) were performed according to standard procedures.
Standard protocol approvals, registrations, and patient consents
All biological materials family history as well as medical and neurophysiological reports were obtained under appropriate informed consent of the patients or their legal guardians. The local ethics committees of the University of Muenster approved the study.
Mutations and clinical presentation of patients
Patient 1 is a female with the mutation R215W on the gene Gjb1. Clinically, she has distal pareses of arms and legs, gait ataxia and distal sensory loss. Age of onset: 22 years. Nerve conduction studies showed an intermediate neuropathy.
Patient 2 is the sister of patient 1, with the same mutation R215W. Clinically, she shows pareses of foot dorsal extension, finger abduction and extension on both sides, distal symmetric sensory loss and absent achilles tendon reflexes. Age of onset: 25 years.
Patient 3 is a male with a mutation R142W. He presents muscle atrophies and pareses of hands and calves, foot drop, distal symmetrical hyp- and dysesthesia of legs. Tendon reflexes are reduced in the arms, absent in legs. Age of onset: ca. 15 years. Nerve conduction studies showed an intermediate neuropathy.
Patient 4 is a female with the mutation V181M. She presents pareses of foot dorsiflexion and small hand muscles, neuropathic pain in feet and hands, distal symmetric hyp- and dysesthesia of feet and fingertips. Tendon reflexes reduced in the arms, absent in legs. Age of onset: ca. 25 years. Nerve conduction studies showed an intermediate neuropathy.
Patient 5 is a male, the son of patient 4 with the same mutation V181M. He presents pareses of foot dorsiflexion, plantar flexion, mild pareses of finger abduction and hypesthesia of feet. He shows high arched feet and hammer toes. Tendon reflexes are absent in arms and legs. Age of onset: 16 years.
Results of nerve conductions studies
Human fibroblast cell culture
Fibroblast cell cultures were performed as described . A 1 mm skin punch biopsy was transferred to DMEM supplemented with 20% fetal calf serum, penicillin/streptomycin and glutamine (D20 medium). The tissue was transferred to a 60 mm plastic Pasteur dish and submersed in D20 medium at standard conditions. After a lawn of fibroblasts had grown, biopsy tissues were removed and the cultures were grown and passaged 3 times before assays were performed.
Cells were lysed in RIPA buffer (50 mM Tris-Cl pH 7.4, 1% NP40, 0.25% sodium deoxycholate, 0.1% SDS, 150 mM sodium chloride) supplemented with protease and phosphatase inhibitors. The same amounts of protein from each sample were resolved under denaturing and reducing conditions on 4-12% NuPAGE gels (Invitrogen) and transferred to polyvinylidene fluoride membranes. Immunoreactive proteins were revealed by enhanced chemiluminescence with ECL (Perkin-Elmer). An antibody against phosphorylated CamKII (Cell Signaling, catalog number: 3361) was used.
Cells were grown on glass coverslips for 24 h to allow cultures to reach 80% confluence. To measure the number of centrosomes, cells were fixed with 4% PFA, permeabilized with methanol at −20°C for 8 min and blocked with 0.5% Triton X-100 in PBS for 30 min at RT. To detect γ-tubulin, cells were incubated overnight at 4°C with a mouse anti-γ-tubulin antibody (GTU-88; Sigma) diluted 1/1000 in PBS containing 0.1% milk and 0.05% Triton X-100. After washing, the cells were incubated for 1 h at RT with Cy3-conjugated goat anti-mouse IgG secondary antibody (Caltag Laboratories) diluted 1/2000 in PBS containing 0.1% milk and 0.05% Triton X-100. The preparations were counterstained with DAPI in Vectashield mounting medium (Vector Laboratories). Fluorescent images were acquired with a microscope (Leica DMR) equipped with a PL APO objective.
One hundred thousand cells were cultured as described above for one day with or without CamKII inhibitors (KN62 or KN93 at a final concentration of 10 μM). Lucifer yellow (LY) was added to the medium (final concentration: 110 μM) and incubated for two hours. Fluorescence was recorded using a Perkin Elmer Victor 4 microplaque reader (excitation: 405 nM, emission: 535 nM).
Statistical analysis was performed using Prism v5.0. Mann–Whitney and chi-square tests were used for trend analysis. The significance threshold was setted at p < 0.05.
Results and discussion
Cells from five transgenic lines created in the laboratory present centrosome overduplications that are linked to mutations in GJB1 . We thus evaluated centrosome duplication in normal and CMTX1 fibroblasts, treated or untreated with the CamKII inhibitor KN93. We observed centrosome overduplication in the fibroblasts from CMTX1 patients, which supports the findings of the study on GJB1 transgenic mice (Figures 3A, B, and 2A). As expected, this overduplication was significantly corrected by KN93 treatment (10 μM ; Figure 2B).
In conclusion, the fibroblasts from five CMTX1 patients showed the same cellular phenotype that we described in GJB1 transgenic mouse models created in the laboratory [1,6], including nuclei anomalies, centrosome overduplication, and impaired connexon activity. As suggested by Matsumoto and Maller , centrosome duplication is linked to CamKII activity. In CMTX1 mice, we have already shown that CamKII inhibitors can revert the phenotype linked to mutations in the GJB1 gene. These results suggest that the phenotype observed in the fibroblasts from CMTX1 patients can also be corrected, at least partially, by treatment with a CamKII inhibitor.
Waggener et al. recently demonstrated that CamKII is involved in myelination mechanisms in the central nervous system (CNS) . They demonstrated that perturbation of CamKII beta is associated with anomalies in CNS glial celll maturation, is involved in anomalies of actin skeleton, and is associated with myelin anomalies. Recently, we demonstrated that the locomotor behaviour of GJB1 mutated mouse models of CMTX1 can be improved by treatment with CamKII inhibitors . In conclusion, the fibroblasts of human CMTX1 patients present the same phenotype as the fibroblasts of mouse models. Moreover, the same molecule (KN93) partially corrects the cellular phenotype of human and mouse fibroblasts as well as locomotor behaviour in mouse models. These findings provide a translational link from the murine to the human system. Although it is still too early to directly apply our results to human patients, for the first time, our results show a potential avenue for therapeutic approaches to CMTX1 treatment.
This study has been funded on by an annual recurrent budget of our unit (NORT). No extra fundings or private grants have been involved in this study.
- Mones S, Bordignon B, Fontés M. Connexin 32 is involved in mitosis. Glia. 2012;60(3):457–64.View ArticlePubMedGoogle Scholar
- Bergoffen J, Scherer SS, Wang S, Scott MO, Bone LJ. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science. 1993;262:2039–42.View ArticlePubMedGoogle Scholar
- Ahmad S, Martin PE, Evans WH. Assembly of gap junction channels: mechanism, effects of calmodulin antagonists and identification of connexinoligomerization determinants. Eur J Biochem. 2001;268(16):4544–52.View ArticlePubMedGoogle Scholar
- Scherer SS, Deschênes SM, Xu YT, Grinspan JB, Fischbeck KH, Paul DL. Connexin32 is a myelin-related protein in the PNS and CNS. J Neurosci. 1995;15(12):8281–194.PubMedGoogle Scholar
- Neumann B, Walter T, Hériché JK, Bulkescher J, Erfle H, Conrad C, et al. Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. Nature. 2010;464(7289):721–7.PubMed CentralView ArticlePubMedGoogle Scholar
- Mones S, Bordignon B, Peiretti F, Landrier JF, Gess B, Bourguignon JJ, et al. CamKII inhibitors reduce mitotic instability, connexon anomalies and progression of the in vivo behavioral phenotype in transgenic animals expressing a mutated GJB1 gene. Front Neurosci. 2014;8:151.PubMed CentralView ArticlePubMedGoogle Scholar
- Torok K, Stauffer K, Evans WH. Connexin 32 of gap junctions contains two cytoplasmic calmodulin-binding domains. Biochem J. 1997;326:479–83.PubMed CentralView ArticlePubMedGoogle Scholar
- Dodd R, Peracchia C, Stolady D, Török K. Calmodulin association with connexin32-derived peptides suggests trans-domain interaction in chemical gating of gap junction channels. J Biol Chem. 2008;283(40):26911–20.PubMed CentralView ArticlePubMedGoogle Scholar
- Sumi M, Kiuchi K, Ishikawa T, Ishii A, Hagiwara M. The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res Commun. 1991;181(3):968–75.View ArticlePubMedGoogle Scholar
- Gess B, Auer-Grumbach M, Schirmacher A, Strom T, Zitzelsberger M, Rudnik-Schöneborn S, et al. HSJ1-related hereditary neuropathies: novel mutations and extended clinical spectrum. Neurology. 2014;83(19):1726–32.View ArticlePubMedGoogle Scholar
- Oh S, Ri Y, Bennett M, Trexler EB, Verselis VK, Bargiello TA. Changes in permeability caused by connexin 32 mutations underlie X-linked Charcot-Marie-Tooth disease. Neuron. 1997;19(4):927–38.View ArticlePubMedGoogle Scholar
- Matsumoto Y, Maller JL. Calcium, calmodulin, and CaMKII requirement for initiation of centrosome duplication in Xenopus egg extracts. Science. 2002;295:499–502.View ArticlePubMedGoogle Scholar
- Waggener CT, Dupree JL, Elgersma Y, Fuss B. CaMKIIβ regulates oligodendrocyte maturation and CNS myelination. J Neurosci. 2013;33(25):10453–8.PubMed CentralView ArticlePubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.